ORLANDO, Fla., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Savvy investors are aware of many of the perils besieging small cap companies and potentially the value of their investments. Foremost among these concerns is a share structure that continues to grow, often driven by convertible debt and other financial actions that lead to adverse valuations for the public.
And while these debt offerings can be necessities for growth, perhaps even survival, the argument of more shares hitting the market clearly impacts the supply/demand ratio. This truism helps highlight the contrast for one company with a share structure that is the antithesis of the aforementioned.
Conversely, innovative medical device maker NanoVibronix Inc. (OTCQB:NAOV) currently reports just 2,623,710 shares outstanding and a market capitalization of $14,430,405 according to OTC Markets in early August (source: http://bit.ly/2avT6f8.) In addition there are 1,948,759 voting Preferred C Shares which can be converted to Common Shares on a 1-1 basis.
Pair this with the fact that NanoVibronix is already producing revenue and has a proprietary product line that is being sold via the company website and internationally through medical product distributors.
In future editions of the Emerging Markets Report we’ll dive into the product and the market for NanoVibronix’s wares. Right now, we just want to draw your attention to a share structure that isn’t frequently seen at this market strata.
In the interim, take a look at the NanoVibronix product line on their official site:
NanoVibronix Inc. is a medical device company headquartered in Elmsford, NY with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and patented surface acoustic wave ultrasound. The company's groundbreaking technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications. The devices accelerate wound healing and provide pain relief. The devices can also be administered at home, without the assistance of medical professionals. The company's products include PainShield® and WoundShield™, which both have CE Mark. The PainShield™ also has FDA clearance. NanoVibronix's catheter based products include the UroShield™ and NG-Shield™ that are both CE Marked. Uroshield reduces pain and prevents infection in urinary catheters. Additional information about the company is available at: www.nanovibronix.com.
About the Emerging Markets Report:
Emerging Markets Report is owned and operated by Emerging Markets Consulting, a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php.
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom.
EMC has been paid 3000 dollars and 9000 restricted shares by NanoVibronix.
Source: Emerging Markets LLC